Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Snyder Biomedical
Tucson, Arizona, United Statessnyderbiomedical.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Snyder Biomedical has completed a proof-of-concept trial for their approach to preventing and treating macular degeneration using L-DOPA, with findings published in the American Journal of Medicine in 2020. They are preparing a placebo-controlled Phase 2 clinical trial to determine if L-DOPA can prevent the development of neovascular age-related macular degeneration in high-risk eyes.
- Therapeutic areas
- Ophthalmology
- Modalities
- Small molecule (L-DOPA)Small molecule (Carbidopa)
- Industry
- Biotech
02
Partnerships
University of Arizona (licensed intellectual property)
Beyond the preview
Go deeper on Snyder Biomedical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Snyder Biomedical.